DE40: DAX holds important support structure; Carl Zeiss gains 7% after earnings

11:48 AM 9 February 2024
  • European markets make slight gains to end the week 
  • Investors focus on individual company results 
  • Barclays, Deutsche Bank and Baader Helvea modify their recommendations

Overall market situation:

This week's last trading session on European markets brings mixed investor sentiment. Most indices on the Old Continent are currently posting marginal intraday gains. The main focus of today's session is on the results of individual listed companies. A revision of the CPI data from Germany confirmed the first reading. 

European companies listed during Friday's trading session are currently trading mixed. Source: xStation 5

The German benchmark DE40 is holding during Friday's session within the limits set by the 50-period moving average (blue curve on the chart, H4 interval). The main levels to watch all the time remain the areas of minima near 16900 points and local peaks near 17120 points.  Source: xStation 5

News:

Ceconomy (CEC.DE) shares are currently losing more than 3% following the publication of worse-than-expected EPS and EBIT results.

FIRST QUARTER RESULTS

Adjusted operating profit EUR 248 million, estimated EUR 241.7 million 

Ebit 218 million euro, estimated 244.7 million euro

EPS 0.30 euro, estimated 0.38 euro

Sales 7 billion euro, estimated 6.92 billion euro

COMMENTARY AND CONTEXT

In 2024, Ceconomy expects a slight increase in total sales adjusted for currency effects and portfolio changes and a marked improvement in adjusted EBIT.

Source: xStation

The shares of Carl Zeiss Meditec (AFX.DE) also performed very well during today's session, gaining nearly 7%. The company's results exceeded the expectations of analysts, who were still cautious in their assessment of the company's business background last time. 

FIRST QUARTER RESULTS

Ebit 43.5 million euro, estimated 41.5 million euro 

Ebit margin 9.2%, estimated 8.98%

EPS 0.42 euro vs. 0.57 euro y/y

Revenues 475. million euro, estimated 469.1 million euro

Revenue from ophthalmic devices 351.1 million euro

Revenues from microsurgery 123.9 million euro

COMMENTARY AND BACKGROUND

Revenues are expected to grow at least in line with market growth.

EBIT margin is expected to gradually improve over the remainder of the year.

EBIT for the full financial year 2023/24 is expected to be close to the previous year's level.

Source: xStation 

Analyst recommendations:

Barclays reiterated an "Overweight" rating on Adidas (ADS.DE) shares. Target price at €218.

Barclays reiterated an "Overweight" rating on shares of Puma (PUM.DE). Target price of €42.

Deutsche Bank upgraded its rating on shares of Verbio (VBK.DE). Target price of €21.

Baader Helvea downgraded its recommendation for the shares of Nemetschek (NEM.DE) to "reduce" from the previous "add" rating. Target price set at €92 

 

Share:
Back

Join over 1 600 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits